NASDAQ · WENA
Anew Medical, Inc.
$0.73-$0.03 (-3.84%)
Anew Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.79% below the high.
Loading market information…
NASDAQ · PKBO · USD
Stock price, earnings
Quote as of Nov 14, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Peak Bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges. Additionally, Peak Bio's leading investigational drug, PHP-303, a small molecule, is on the verge of commencing a Phase II dose clinical trial for the rare condition Alpha1 anti-trypsin deficiency (AATD). The company's operations are situated in Palo Alto, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.73-$0.03 (-3.84%)
Anew Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.79% below the high.
$0.86-$0.05 (-5.91%)
Phio Pharmaceuticals Corp.’s quoted price sits in the lower half of its reported 52-week range, 79.41% below the high.
$1.85+$0.23 (+14.2%)
BiomX Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.5% below the high.
$0.07-$0.01 (-6.68%)
Bellicum Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.29% below the high.
$0.07-$0.10 (-60.05%)
TFF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.41% below the high.
$0.11$0.00 (0.0%)
Longevity Health Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.41% below the high.
$0.50$0.00 (0.0%)
TC Biopharm (Holdings) Plc’s quoted price sits in the lower half of its reported 52-week range, 99.9% below the high.
$0.00$0.00 (0.0%)
Infinity Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.15% below the high.
